Pharmadvance SRL
4.0 FTEPharmadvance reported total assets of €1.07m at the end of the 2025 financial year (annual accounts filed with the NBB on 08 Jul 2026), with 4 full-time equivalents.
The score of Pharmadvance shows with a free account.
See the score- Summary? / 5
- Balance sheet strength
- Liquidity
- Repayment capacity
- Profitability
- Trajectory
- Compliance and register
- Position in its sectorvs peers
- Supplier creditat 30 d
- Borrowing capacityborrowable
- Valuationcentral
Visible once signed in: create your account, the 14-day Pro trial is free.
Key figures 2025
Change 2022 → 2025: Equity +138 % Total assets -14 % Headcount (avg FTE) -2 %
Accounts of the company itself (not consolidated).
The full file covers 9 financial years; a free account shows 2. →Deterministic calculation on the filed accounts, no AI. Dispute the score or report an error
Pharmadvance's annual accounts
Filed annual accounts
- Year ended 31 Dec 2025filed on 08 Jul 2026
- Year ended 31 Dec 2024filed on 21 Aug 2025
- Year ended 31 Dec 2023filed on 23 Oct 2024
- Year ended 31 Dec 2022filed on 29 Oct 2023
- Year ended 31 Dec 2021filed on 02 Sep 2022
Pharmadvance's financial analysis
- Solvency8.5%sector median: 41.5%
- Current ratio
- Net margin
- ROE
- Financial debt / EBITDA
- Interest coverage
- Days sales outstanding (DSO)
Management and control of Pharmadvance
Pharmadvance's publications in the Belgian Gazette
Company number, VAT number and registered office
- Company number (CBE)
- 0671.818.337
- VAT number
- BE0671818337
- Peppol
- Registered · 0208:0671818337 · as of 10 Nov 2026
- Legal form
- SRL
- Incorporated
- 24 Feb 2017
- Registered office
- 7950 Chièvres
- Size
- Micro · 4.0 FTE
- Latest accounts
- 2025 · filed on 08 Jul 2026
- Activity
- Retail sale of pharmaceutical products (NACE 47730)
Pharmadvance (SRL) has been based in Chièvres since 2017, active in: retail sale of pharmaceutical products. For 2025, it reports a net profit of 43,820 € and equity of 91,136 €; its revenue is not published. With 4.0 full-time equivalents, it is a micro-enterprise by headcount. Its solvency stands at 8.5%, below the median of its sector (41.5%).
Companies similar to Pharmadvance
Companies in the same business, of comparable size and area, outside its group.
- Pharmacie DE Neef - Duez Retail sale of pharmaceutical products Mons · balance sheet 181,026 €
- L.V.G. Pharma Retail sale of pharmaceutical products Puurs-Sint-Amands · balance sheet €1.06m
- Van Geem Retail sale of pharmaceutical products Antwerp · balance sheet €1.08m
- Verhaeghe Pharma Retail sale of pharmaceutical products Izegem · balance sheet €1.05m
- Capavita Retail sale of pharmaceutical products Schoten · balance sheet €1.09m
- Apoteek Mommaert Retail sale of pharmaceutical products Beersel · balance sheet €1.09m
- Novaka Pharma Retail sale of pharmaceutical products Nivelles · balance sheet €1.10m
- Apotheek Devos Retail sale of pharmaceutical products Halle · balance sheet €1.02m
Frequently asked questions about Pharmadvance
What is the revenue of Pharmadvance?
Pharmadvance files its accounts in a format where revenue is optional: it is not published for 2025.
What is the VAT number of Pharmadvance?
In Belgium, the VAT number is the company number prefixed with BE: BE0671818337 for Pharmadvance, if the company is VAT-registered. Its company number (CBE) is 0671.818.337.
Where is the registered office of Pharmadvance?
According to the CBE register, the registered office of Pharmadvance is in 7950 Chièvres.
What is the equity of Pharmadvance?
At the close of the 2025 financial year, the equity of Pharmadvance amounts to 91,136 €, a solvency of 8.5% of total assets.
How many people work at Pharmadvance?
4.0 full-time equivalents on average according to the 2025 social balance sheet.
Who manages Pharmadvance?
The register lists 4 active mandates at Pharmadvance. Names and roles are in the full file, with the deeds published in the Belgian Gazette.
The full file of Pharmadvance
Directors and mandates, ownership network, Gazette deeds, ten years of accounts and ratios, Excel export, and Idonis's analysis in one question.
Open the full file →